BLUE BELL, Pa., May 12, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, announced today
that MDB Capital Group has recognized Inovio with its CLARUS Award,
given annually to publicly traded companies possessing
market-changing intellectually property (IP) assets. The award was
presented at the second annual Bright Lights Conference in New York
City, a meeting that provides institutional investors with a venue
to discover the largely unrecognized value of intellectual
Christopher A. Marlett, CEO of MDB Capital Group, said, “Inovio
Pharmaceuticals was the top company in its industry with the
highest ‘Tech Score’ and number of patent grants, and we are
honored to recognize their achievements in driving IP as an asset
class and the impact they are making on innovation in America.”
MDB’s “Tech Score” measures the industry impact of a company’s
patents, as it is an indicator of a company’s competitive position.
It is based upon an analysis of the citation ratios of a company’s
patents relative to its peer group.
Inovio’s DNA vaccine pipeline and proprietary delivery
technology were selected from MDB’s 2011 group of “Best and
Brightest” small-cap companies, a group that is advancing some of
today’s most innovative and market-leading intellectual property.
Inovio is one of 40 public companies ranking in the 90th percentile
for its respective technology leadership from more than 1,500
small-cap companies with granted U.S. patents, as rated by MDB.
Dr. J. Joseph Kim, Inovio’s president and CEO, said:
“Intellectual property is the lifeblood of medical innovation and
Inovio is proud to be recognized for its preeminent patent estate
for our pipeline of DNA vaccines and our innovative vaccine